StockData

HUTCHMED (China) vs OPKO Health

HCM and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCM and OPK compare

OPKO Health grew revenue faster over the last twelve months (−11.5% versus −13.0% for HUTCHMED (China)).

HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −12.4% at OPKO Health.

OPKO Health scores higher on the StockData Score (9 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCMOPK
Size and price
Market cap–$1.2B
Share price$14.40$1.62
Change, 1 year−4.5%26.6%
Change, 5 years−59.1%−60.8%
Beta (5Y)0.750.36
Employees1092,275
StockData Score
Total score59 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score33
Health score24 (better)
Dividend score00
Valuation
P/S–2.1×
P/B–1.0×
EV/EBITDA–22.0×
FCF yield–−11.1%
Fair value–$1.55
Margin of safety–−4.7%
Growth
Revenue growth (TTM)−13.0%−11.5% (better)
Revenue growth, 5Y average19.2% (better)−15.8%
Net income growth (TTM)1111%–
EPS growth (TTM)1200%–
Profitability
Gross margin38.7%40.8% (better)
Operating margin−7.1% (better)−8.2%
Net margin83.3% (better)−12.4%
FCF margin−14.4% (better)−22.8%
Return on equity36.7% (better)−5.9%
Return on invested capital–−4.0%
Financial health
Debt / equity0.090.00 (better)
Net debt / EBITDA–−7.19
Interest coverage−13.7×–
Current ratio5.64 (better)3.35
Altman Z-score–−0.21
Piotroski F-score44
Dividends and buybacks
Buyback yield–3.9%
Shareholder yield–3.9%
Ownership
Held by institutions0.51%27.2%
Held by insiders0.44%43.6%
Insider net buying, 12 months–−$13.2K
Short interest, % of float–7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.